Neal, J. W., Cho, B. C., Wang, Y., Wu, L., Felip, E., Cui, J., Spira, A. I., Marmarelis, M. E., Ichihara, E., Lee, S., Yang, J. C. H., Michels, S. Y. F., Curtin, J. C., Lu, X., Anastasiou, Z., Leconte, I., Trani, L., Shah, S., Tomasini, P. (2026). Overall survival of first-line amivantamab plus lazertinib in atypical EGFR -mutated advanced non-small cell lung cancer (NSCLC): Updated results from the CHRYSALIS-2 study.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.8501